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Local induction of angiotensin-converting enzyme as a mecha-
nism contributing to progressive renal disease. Angiotensin
Converting Enzyme (ACE) or Kininase II has a pivotal role
determining the local activity of the renin angiotensin and
kallikrein kinin systems. Angiotensin II (Ang II), a main hor-
mone of the renin system, has a well established participation
as a renal injury agent in models of renal disease with tubulo-
interstitial fibrosis. Although, since its discovery, ACE has been
known to convert Ang I to Ang II, and to inactivate bradykinin
(BK), only recently has been emerged evidence for a role of
BK with renal protective and antifibrotic effects opposing Ang
II. Pertinent to the tubulointerstitial injury, where infiltration
and proliferation of macrophages and fibroblast occur, ACE
also regulates the levels of the natural hemoregulatory peptide,
N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP). Owing the im-
portance of tissue ACE, its distribution was studied in several
models of renal injury. The results showed increased ACE in
proximal tubules and ACE induction in the cell infiltrated
tubulointerstitium (macrophages and myofibroblasts) of in-
jured kidneys from hypokalemic, Goldblatt hypertensive, Ang
II and phenylefrine infused rats, and in both human diabetic
and membranous nephropathies. ACE, in addition to Ang II
generation, may play a pathogenic role through the hydrolysis
of BK and Ac-SDKP. Thus, local increase in ACE can be a
novel mechanism involved in tubulointerstitial renal injury,
providing, from an anatomical ground, a pathological basis for
the putative deleterious effect of ACE in the diseased kidneys,
and the beneficial effect of ACE inhibition.
As stated by Klahr and Morrissey [1] and Mezzano,
Ruiz-Ortega, and Egido [2] in two comprehensive re-
views, a number of kidney diseases are driven, in part,
by the effects of angiotensin II (Ang II) to end-stage
renal disease. High levels of Ang II via growth factors
and cytokines, promote cell growth, inflammatory re-
sponse, and fibrosis, contributing to progressive kidney
disease [1, 2].
Rather than the circulating renin-angiotensin system,
it is the local system mainly responsible for the local levels
of Ang II, as evidenced by the large differences observed
between circulating and renal levels of Ang II.
Because of the pivotal role of angiotensin-converting
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enzyme (ACE) in Ang II generation, in this article we
review, from a morphologic ground, the possible contri-
bution of ACE to progressive renal disease, in particular
its cardinal feature, tubulointerstitial fibrosis. We pro-
pose, as a working hypothesis, that in diseased kidneys
exist an increased expression of ACE in proximal tubules
and also an induction of the enzyme at the tubulointer-
stitium. At these sites, ACE, acting on its natural sub-
strates, can imbalance the vasoactive hormones Ang II
and bradykinin in favor of the generation of the vasocon-
strictor, profibrotic, proliferative, sodium-retaining Ang
II. At the same time, ACE can metabolize the vasodila-
tor, antifibrotic, sodium excretory bradykinin (BK), and
perhaps also degrade the hemoregulatory, antiprolifera-
tive N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), lead-
ing to a vicious circle that contributes to the progression
of renal diseases.
ACE, a multifunctional enzyme
Angiotensin-converting enzyme (ACE; kininase II,
E.C. 3.4.,15.1) is a zinc metallopeptidase acting mainly
as a dipeptidylpeptidase that hydrolyzes a number of pep-
tide substrates in vitro. However, in the context of both
physiology and pathology of the kidney, the most relevant
substrates are the vasoactive hormones angiotensin I
(Ang I) and BK, and the hemoregulatory peptide, Ac-
SDKP. The molecular properties and genetic structure
of ACE/kininase II indicates that this enzyme is an-
chored into the plasma membrane by a C-terminal hy-
drophobic segment and exists in two isoforms, germinal
and somatic. The germinal form, a 90 to 100 kD glycopro-
tein, is restricted to the testis, where it is expressed
uniquely in germinal cells during maturation of sperma-
togenesis [3] and is required for achieving in vivo fertil-
ization [4] and male fertility, as evidenced by the finding
that male homozygous ACE / mice display reduced
fertility [5]. The somatic isoform, a 150 to 180 kD glyco-
protein, is expressed in vascular endothelial cells and at
the brush border of renal proximal convoluted tubule,
among other cells. Since germinal ACE is restricted to
the testis, hereafter the term ACE will be referred solely
to the somatic form.
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The molecular cloning of ACE reveals two very similar
domains, each having a functional active site. These two
active sites display highly similar kinetic parameters for
the natural substrates (Ang I, BK) [6], except for Ac-
SDKP, which is the preferred substrate for the N-termi-
nal active site [7, 8].
Among its natural substrates, BK is the one for which
ACE displays the most favorable kinetic parameters.
Indeed, the (Michaelis constant, affinity constant) Km is
about 88 times lower for BK than for Ang I (0.18 mol/L
vs. 16 mol/L), with a Kcat/Km (specificity constant) about
25 times higher for BK than for Ang I (39 to 61 mol/L1
s1 vs. 1.5 to 2.5 mol/L1 s1) [6].
In view of the kinetics data, and the fact that since its
discovery, ACE has been known to convert Ang I to
Ang II, and to inactivate bradykinin [9], it is puzzling
why this enzyme has been considered mainly as an “an-
giotensin I–converting enzyme,” underestimating its role
of inactivating BK and therefore regulating the activity
of the kallikrein-kinin system. This point is relevant to
the topic of this article as there is increasing evidence
of the renoprotective effect of kallikrein [10, 11] and the
antifibrotic effects of BK [12, 13].
Pertinent to the nature of the tubulointerstitial injury,
where infiltration and proliferation of macrophages and
fibroblast occur, ACE regulates the levels of the Ac-
SDKP, a natural regulator of hemopoietic cell prolif-
eration. Ac-SDKP is hydrolyzed preferentially by the
N-active site of ACE with kinetic constants within the
range of physiologic substrates, with a Km 31 mol/L
and a Kcat/Km 0.5 mol/L1 s1, a specificity constant
approaching that of Ang I [7]. This suggests that ACE
is involved in the in vivo regulation of the local concen-
tration of this hemoregulatory peptide. The 7-fold in-
crease in the plasma concentration of AcSDKP observed
in normal volunteers after the acute administration of
an ACE inhibitor (captopril), demonstrates the role in
vivo of ACE in the metabolism of this hemoregulatory
tetrapeptide [14, 8]. The implications of this novel func-
tion of ACE in relation to the tubulointerstitial injury
is discussed below.
Localization of ACE in normal kidneys
Endothelial cells contain an abundant amount of
ACE; however, kidney epithelial cells are much richer
than endothelial cells. In fact, the human kidney has 5
to 6 times more ACE per wet weight than the lung [15].
Although the enzymatic activity of ACE in the kidney
was described mainly concentrated in proximal tubules
with less activity in glomeruli [16], the studies addressing
the localization of the immunoreactive ACE protein
have given dissimilar results. Thus, the ACE protein has
been described all along the nephron [17], in all arteries
and arterioles of the cortex and in most glomeruli [18], in
proximal tubules, and most glomeruli and renal cortical
arteries [19]. Most of the previous studies have been
performed using antibodies raised against the whole en-
zyme purified from the lung and are likely not to discrimi-
nate between the plasma and the native membrane-
bound form at the site of synthesis.
The elucidation of the structure of human ACE has
allowed the generation of specific antibodies directed
against discreet segments of the enzyme. Thus, Wei et al
[20] transfected Chinese hamster ovary cells with a full-
length cDNA encoding human ACE and obtained the
expression of an enzyme structurally, immunologically,
and enzymatically identical to human kidney ACE. The
cell line produced ACE as a membrane-bound ecto-
enzyme with an intracellular C terminus, as detected
using an antibody raised against the last 20 C terminus
amino acids. In addition, the transfected cells produced
a secreted form of ACE. Neither this secreted ACE, nor
the purified enzyme from human plasma was recognized
by the C-terminus antibody. Consequently, the secreted
and circulating ACE, derived from the membrane-bound
form, is devoid of the C-terminal region by a post-transla-
tional proteolytic cleavage.
To localize ACE we followed the protocol described
by Wei et al [20] and generated specific antibodies against
the same intracellular carboxyl terminal sequence of hu-
man ACE (peptide 1258–1277). It is important to empha-
size that these antibodies are directed against the intra-
cellular domain of the enzyme, therefore recognizing
ACE at the site of synthesis in its native, membrane-
bound form, and do not recognize the soluble or circulat-
ing enzyme, which is truncated in this region when re-
leased from the cell surface [20].
The specificity of these antibodies has been well estab-
lished by immunohistochemistry and Western blotting
[3, 20–23].
In control rat kidneys the presence of ACE is detected
mainly in the brush border of proximal tubular cells. The
proximal tubules containing ACE are observed in the
inner cortex and in the outer stripe of the outer medulla
and they correspond to straight proximal (S3) segments
of cortical nephron and to the more tortuous S3 segments
derived from juxtamedullary nephron (Fig. 1 A and B)
[21–23].
ACE immunostaining was not detected in proximal
convoluted tubule (S1), in other tubular structures of the
cortex (i.e., distal convoluted tubules, connecting tubules,
cortical collecting ducts), or in glomeruli. No ACE was
observed also in the interstitial space (Fig. 1 A and B),
where in normal conditions few macrophages and fibro-
blasts reside [24]. This rather limited distribution of ACE
in the normal rat kidneys may be due to the fact that,
compared to other species, the rat kidney has a lower tu-
bular ACE content [15, 25]. In contrast to human kid-
neys, in which ACE immunostaining is observed all
along the proximal tubule, in the rat it is restricted to the
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Fig. 1. Distribution of angiotensin-converting enzyme (ACE) in normal and diseased kidneys. (A, C, E ) correspond to representative renal
sections (Bouin’s fixed tissue) from control rats, Goldblatt hypertensive (nonclipped) rats, and angiotensin II (Ang II)–infused rats, respectively.
(B, D, F ) correspond to representative renal sections (Methyl Carnoy’s fixed tissue) from control rats, hypokalemic rats, and phenylefrine-infused
rats, respectively. In renal sections from control rats (A and B), ACE is detected in moderate intensity over the brush border of the S3 segment
of the proximal tubule, whereas a stronger staining is observed in the brush border of renal sections from Goldblatt hypertensive (C), hypokalemic
(D) Ang II (E), and phenylefrine-infused rats (F). While no ACE immunostaining is observed in the tubulointerstitium of control rats (A and
B), a strong ACE staining is evident in all diseased kidneys (C, D, E, F). Arrows indicate the presence of ACE in the activated tubulointerstitium.
The infiltrating cells observed in the activated tubulointerstitium correspond mostly to macrophages (ED1) and myofibroblasts (-SMA)
[21, 22]. All figure parts are the same magnification, scale bar  50 m. Control corresponds to renal section from either sham-operated or vehicle-
infused rats.
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straight portion (S3) of the proximal tubule located at
the outer zone of the medulla [26]. The localization of
ACE to the late segments of the proximal tubules is in
accordance with previous studies in rat kidneys, in which
ACE activity has been described to be 10 and 5 times
higher in the inner cortex and outer medulla than in
the outer cortex, respectively [27], and also with data
obtained in rabbit microdissected nephrons, in which
ACE activity was found to be highest in the pars recta
(S3) and decreased toward the convoluted portion of
the proximal tubule (S1) [28].
Local induction of ACE in diseased kidneys
In contrast to renal sections from control rats, in which
ACE immunostaining was detected in moderate inten-
sity mainly over the brush border of the S3 segment of
the proximal tubule and absent in the tubulointerstitium
(Fig. 1 A and B), in the diseased kidneys the content
and distribution ACE differed markedly (Fig. 1 C, D,
E, F). Thus, a stronger ACE staining was observed in
the brush border of renal sections from Goldblatt non-
clipped hypertensive (Fig. 1C), hypokalemic (Fig. 1D),
Ang II (Fig. 1E), and phenylephrine-infused rats (Fig.
1F). Moreover, ACE was induced in the activated tubu-
lointerstitium in all diseased kidneys as evidenced by
the presence of a strong ACE immunostaining in renal
biopsies from Goldblatt hypertensive (Fig. 1C), hypo-
kalemic (Fig. 1D), Ang II (Fig. 1E), and phenylefrine-
infused rats (Fig. 1F). At this site, the presence of ACE
was observed coinciding with infiltrating cells, corre-
sponding mainly to macrophages and myofibroblasts,
ED1, and -smooth muscle actin (-SMA)-positive cells,
respectively [21, 22].
The tubulointerstitial areas with ACE corresponded
to fibrotic areas, as evidenced by the deposition of colla-
gen III [21, 22] and positive staining with picrosirius red.
These fibrotic areas were also often observed around dam-
aged tubules evidenced by its atrophic and dilated phe-
notype (Fig. 1 C, F) and by the expression of the chemo-
tactic peptide, osteopontin [21, 22].
With the same technique used in the experimental
models in rats, we have described increased ACE in
proximal tubules and ACE induction in the tubulointer-
stitium in renal biopsies from human diabetic nephrop-
athy and idiopathic membranous nephropathy [29, 30].
Thus, increased ACE in proximal tubules and induc-
tion of the enzyme in the activated tubulointerstitium
was observed in hypokalemic rats (Fig. 1D) [21], Gold-
blatt hypertensive (Fig. 1C) rats [abstract; Jeanneret
et al, Hypertension 37:1038, 2001], phenylephrine-infused
rats (Fig. 1F) [abstract; Vio et al, Hypertension 37:1043,
2001], angiotensin II–infused rats (Fig. 1E) [22], and
in renal biopsies from diabetic nephropathy [29] and
proteinuric idiopathic membranous nephropathy [30].
Up-regulation of ACE in the kidney has been described
in BSA-overloaded rats, which develop massive protein-
uria with UVprot values of 538  89 mg/24 h versus
3  1 mg/24 h of control rats [31], suggesting that ACE
induction in the kidney may be responsible for the tubu-
lointerstitial lesions observed in renal diseases associated
with persistent proteinuria. However, increased ACE in
the kidney and neoexpression of the enzyme is a rather
common finding in diseased human kidneys, as described
by Metzger et al [26], and also in other tissues during
parenchymal remodeling (vide infra).
In fact, the induction of ACE in the rat kidneys from
the experimental models presented in this article, mainly
models without or with minimal proteinuria, is in agree-
ment with previous reports from Navar’s group, who de-
scribed increased renal ACE enzymatic activity in both
the nonclipped Goldblatt hypertensive rat kidney and in
the Ang II–infused rat kidneys [32, 33]. More recent work
from the same group described increased proximal tubule
ACE binding by quantitative in vitro autoradiographic
analysis [34]. Although these models have suppressed
renin in the kidney, they display high levels of Ang II in
the kidney, suggesting the contribution of the increased
ACE to the levels of Ang II [32, 33]. More recently, it
has been demonstrated in Goldblatt hypertensive dogs
a selective increase in intrarenal ACE activity in the non-
clipped kidney with unaltered ACE activity in clipped
kidneys, the increased ACE activity being responsible
for the elevated levels of renal angiotensin II [35].
Local induction of ACE in the macrophages and myo-
fibroblasts infiltrated the renal interstitium it is also ob-
served at other tissue sites, like in the heart during patho-
logic processes in which ACE induction occurs in the
activated cardiac interstitium. The heart normally con-
tains very low levels of ACE, located mainly in coronary
endothelial cells. However, during ventricle hypertrophy,
ACE mRNA and ACE activity increase dramatically when
the interstitium is infiltrated by activated macrophages
and fibroblasts [36]. The interstitial activated cells and
endothelial cells in hypertrophied vessels and capillary
networks contain high levels of ACE. Similarly, ACE
induction is observed in the cardiac interstitium during
experimental ischemia, where induced ACE is present
in macrophages and myofibroblasts [37–39].
The functional consequences of this induction may
be similar in both organs, contributing to local effects
determined by the interstitial levels of Ang II and BK.
ACE effects beyond vasoactive hormones
As mentioned before, ACE, in addition to the effects
on Ang II formation and BK degradation, regulates the
levels of the tetrapeptide Ac-SDKP, a natural inhibitor
of hematopoietic cell proliferation [40]. The N-active site
of ACE hydrolyzes Ac-SDKP with kinetic constants
within the range of physiologic substrates (i.e., affinity
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and specificity constant approaching that of Ang I) [7],
suggesting its participation in the in vivo regulation of
the local concentration of the hemoregulatory peptide.
Moreover, the inhibition of ACE in normal volunteers
increases by a 7-fold the plasma concentration of Ac-
SDKP, demonstrating in vivo the role of ACE in the
metabolism of this hemoregulatory tetrapeptide [14, 8].
More recently it has been demonstrated in vitro that Ac-
SDKP inhibits DNA and collagen synthesis in cardiac
fibroblasts, suggesting that it may be an endogenous reg-
ulator of fibroblast proliferation and collagen synthesis
in the heart [41]. Also, in Goldblatt hypertensive rats
the long-term administration of Ac-SDKP has shown inhi-
bition of monocyte/macrophage infiltration, cell prolifer-
ation, and collagen deposition in the left ventricle of
hypertensive rats [42]. Similarly, in the aldosterone-salt
hypertensive model of cardiac and renal fibrosis, the long-
term administration of Ac-SDKP prevented increased col-
lagen deposition and cell proliferation in the heart and
kidneys [43]. Furthermore, Ac-SDKP inhibits the growth
of cardiac fibroblasts and also inhibits TGFbeta1 (TGF1)-
stimulated phosphorylation of Smad2 [44]. Although ad-
ditional studies are required in other models of renal
fibrosis, the available data suggest that the administra-
tion of Ac-SDKP is able to ameliorate cardiac and renal
fibrosis in two hypertensive animal models. Since ACE
inhibitors increase plasma and tissue Ac-SDKP, and this
tetrapeptide decreases cardiac and renal fibrosis, local
ACE induction by decreasing its local levels could con-
tribute to fibrosis by an Ang II–independent mechanism.
Thus, it is feasible that Ac-SDKP could participate in
the antifibrotic effect of ACE inhibitors.
More recently it has been described as a novel biologic
function of Ac-SDKP to act at nanomolar concentra-
tions, with the ability to interact directly with endothelial
cells and to elicit an angiogenic response in vitro and in
vivo [45]. Ac-SDKP stimulates in vitro endothelial cell
migration and differentiation into capillary-like struc-
tures, and enhances the secretion of an active form of
matrix metalloproteinase-1. In vivo, Ac-SDKP promotes
a significant angiogenic response in the chicken embryo
chorioallantoic membrane, in the abdominal muscle of
the rat, and induces the formation of blood vessels in
Matrigel plugs implanted subcutaneously in the rat [45].
Also, the kallikrein system has demonstrated a contribu-
tion to angiogenesis [46], and furthermore, it has been
described that the proangiogenic effect of ACE inhibi-
tion is mediated by the BK B2 receptor pathway [47].
Thus, locally induced ACE by decreasing local levels of
Ac-SDKP and BK could impair angiogenesis of the renal
microvasculature. This could explain, in part, the obser-
vation that tissue inhibition of ACE activity stimulates
angiogenesis in vivo [48].
Imbalance between ACE and kallikrein: Contribution
to progressive renal disease
The imbalance due to local ACE induction resulting
in increased local formation of Ang II and increased BK
degradation favors progression of the renal disease. In-
terestingly, in some of the models discussed in this article,
in addition to the increased ACE, a decrease of kallikrein
is observed. Thus, there has been described decreased
kallikrein in hypokalemia, Goldblatt hypertension, dia-
betes, and phenylephrine-infused rats [21, 23, 49] [ab-
stract; Vio et al, Hypertension 37:1043, 2001]. The physi-
ology and pathophysiology of the kallikrein system is
beyond the scope of this article; therefore, only a few ar-
ticles related to the topic will be cited. The kallikrein-
kinin system has a renoprotective effect—as evidenced
by increased susceptibility of a low kallikrein rat strain
to renal damage [11], salt-induced renal injury in Dahl
salt-sensitive rats is reversed by adenovirus-mediated
kallikrein gene delivery [10]; similarly, kallikrein gene de-
livery attenuates hypertension and protects against renal
injury and cardiac remodeling in the rat remnant kidney
model of chronic renal failure [50]. Moreover, in cardiac
fibroblasts BK induces a reduction in collagen type I and
III gene expression by a prostacyclin-mediated effect
[12], and in vivo BK B2 receptor activation reduces renal
fibrosis [13].
Thus, in addition to the imbalance secondary to ACE
induction in the diseased kidney, a decreased kallikrein
in the kidney could lead to a vicious circle that would
further imbalance the levels of vasoactive in favor of the
vasopressor, profibrotic, proliferative, sodium-retaining
Ang II, and against the vasodepressor, antifibrotic, and
sodium excretory BK and antiproliferative Ac-SDKP.
At least two main consequences can potentially have
the local induction of ACE in the models previously de-
scribed: progressive tubulointerstitial fibrosis, as dis-
cussed earlier in this article; and impaired sodium excre-
tion, or salt-sensitive hypertension. The mechanisms of
renal injury leading to salt-sensitive hypertension has been
discussed recently in detail by Johnson [51], and is be-
yond the scope of this article.
Is there a common mechanism for induction of ACE
in the diseased kidney?
At present, a mechanism for the up-regulation and
local induction of ACE is hypothetical; however, local
ischemia is a possible common mechanism for its induc-
tion in the kidney.
ACE in the kidney originates mainly in the S3 proxi-
mal tubule segment, located in the inner cortex and outer
stripe of the outer medulla, a zone with low oxygen ten-
sion in normal conditions as evidenced by direct mea-
surements. Using oxygen microelectrodes to describe
oxygen tensions, there is a range of 30 to 36 mm Hg of
pO2 [52].
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According to Fine’s [53] hypothesis, if in vivo hypoxia
of the kidney were to occur at an early stage of the pro-
gressive kidney disease, this would be expected to affect
the already low oxygen tension of the outer medulla and
inner cortex.
Hypoxia has been shown to induce a 2-fold increase
in ACE content in the kidney, as detected by quantitative
binding of 125I-351A, a lisinopril derivative, and by ACE
activity measured by espectrophotometric assay [54].
Moreover, ACE content and ACE mRNA expression
are increased 3- and 2-fold, respectively, by vascular en-
dothelial growth factor (VEGF) [55], which in turn is
well known to be up-regulated by hypoxia [56].
As discussed by Johnson [51] in at least three of the
models where ACE induction was observed: hypokale-
mia, Ang II, and phenylephrine infusion, [21, 22, 57], the
renal injury is greatest in the outer medulla and in the
cortex adjacent to the medulla, suggesting a chronic hy-
poxia effect. Along with Fine’s [53] hypoxia hypothesis
for a common mechanism for the progression of different
types of renal diseases other than proteinuria, induction
of ACE secondary to ischemia could be common mecha-
nism for renal progressive diseases.
CONCLUSION
Induction of ACE in the kidney has been observed
in different experimental models of disease and in two
human renal diseases, regardless of the initial cause
of the disease or the presence or absence of proteinuria.
Regardless of the initial stimuli, ACE is induced at the
tubulointerstitium, where it can further contribute to the
progression of the renal damage by generating local Ang
II, and degrading both BK and Ac-SDKP, leading to a
vicious circle with more cell infiltration and fibrosis.
Thus, more local ACE will increase Ang II and decrease
BK, producing an imbalance between the renin and kalli-
krein systems. Further imbalance would be induced by
a decreased kallikrein in the kidney. In several of the
models discussed here, a decreased kallikrein is observed,
leading to a vicious circle that would further imbalance
the levels of vasoactive hormones in favor of the vaso-
pressor, profibrotic, proliferative, sodium-retaining Ang
II, and against the vasodepressor, antifibrotic, and so-
dium excretory BK and antiproliferative Ac-SDKP.
The observation of ACE induction in tubules and in-
terstitium of diseased kidneys should be extended in the
future to other types of progressive renal disease, which
may provide a pathologic basis for the putative deleteri-
ous effect of ACE in the diseased kidney and a common
mechanism for progressive renal disease.
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